Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD5 CAR-NK in Relapsed/Refractory T-Cell Malignancies
NCT06909474Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD5 CAR-NK cells (Chongqing Precision Biotech) in t-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma, sponsored by Chongqing Precision Biotech. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 28 days, Objective Response Rate at 3 months and 3 more. Started Mar 2025; status: recruiting.
02
Drugs
anti-CD5 CAR-NK cells (Chongqing Precision Biotech)
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoma
Beyond the preview
Go deeper on NCT06909474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909474.